TECX
Tectonic Therapeutic, Inc. Common Stock
stock NASDAQ

ISPR, TECX, QCLS, TYRA

# Biggest Winners in Small Caps (Recent/Last Trading Day Movers)
Small-cap gainers were led by biotech and healthcare names, often driven by clinical updates, insider buying, or sector momentum. Top performers included:
* PRSO — Peraso Inc. (semiconductor company focused on mmWave wireless tech, including 60 GHz solutions for defense, wireless access, etc.) Massive surge: +151.54% to \~$2.04 (huge volume \~366M shares). Reason: Primary catalyst was the March 6, 2026 announcement that its 60 GHz mmWave beamforming tech was selected by Israeli defense contractor InTACT for a next-generation military drone Identification Friend or Foe (IFF) system in contested environments. This defense win sparked viral buying in penny stock circles.
* Insider activity: Limited recent data; some prior board additions and strategic talks (e.g., with Mobix Labs),
* EDSA — Edesa Biotech, Inc. (biotech developing treatments for inflammatory/dermatological/respiratory conditions, e.g., ARDS). Big surge: +80.61% to \~$6.52 (volume \~28–32M shares). Reason: Momentum from promising clinical data/results in ARDS treatment (e.g., Phase 3 paridiprubart study showing mortality improvements), plus positive FDA designations boosting confidence. Broader biotech rally in small caps contributed. Insider activity: Notable recent CEO insider buying (multiple purchases reported in early March 2026, including fresh share buys signaling confidence from leadership).
* ANTX — AN2 Therapeutics, Inc. (biopharma focused on boron chemistry for infectious diseases, lead candidate epetraborole for NTM lung disease, etc.). Surge: +66.67% to \~$2.85 (volume notable). Reason: Plans to advance oral epetraborole into Phase 2 for Polycythemia Vera (PV), plus $40M private placement financing and other pipeline progress (e.g., FDA clearances for trials in M. abscessus). Biotech pipeline momentum drove gains.
* DAWN — Day One Biopharmaceuticals, Inc. (biopharma, oncology focus; OJEMDA for pediatric low-grade glioma, etc.). Huge surge: +65.88% to \~$21.20 (volume \~76M shares). Reason: Major catalyst was announcement of acquisition by Servier (French pharma) for \~$2.5B to expand rare oncology portfolio—classic M&A premium drove the spike. Also strong OJEMDA sales momentum and 2026 revenue guidance ($225M–$250M).
* TECX — Tectonic Therapeutic, Inc. (biotech developing novel therapies, e.g., TX45 for pulmonary hypertension, TX2100 for HHT).Surge: +28.80% to \~$35.87 (hit new highs around $28–$35 range). Reason: Positive Phase 1b topline data for TX45 (hemodynamic improvements in PH-HFrEF), advancing to Phase 2 trials (APEX data expected 2026), plus strong cash position/runway. Biotech clinical momentum and analyst "Buy" ratings (targets up to $81+) fueled it. Insider activity: Recent insider buying (e.g., CEO and CFO purchases in Feb 2026 at \~$21/share levels, totaling significant value; net buys over sales in recent periods).

ISPR, TECX, QCLS, TYRA

# Biggest Winners in Small Caps (Recent/Last Trading Day Movers)
Small-cap gainers were led by biotech and healthcare names, often driven by clinical updates, insider buying, or sector momentum. Top performers included:
* PRSO — Peraso Inc. (semiconductor company focused on mmWave wireless tech, including 60 GHz solutions for defense, wireless access, etc.) Massive surge: +151.54% to \~$2.04 (huge volume \~366M shares). Reason: Primary catalyst was the March 6, 2026 announcement that its 60 GHz mmWave beamforming tech was selected by Israeli defense contractor InTACT for a next-generation military drone Identification Friend or Foe (IFF) system in contested environments. This defense win sparked viral buying in penny stock circles.
* Insider activity: Limited recent data; some prior board additions and strategic talks (e.g., with Mobix Labs),
* EDSA — Edesa Biotech, Inc. (biotech developing treatments for inflammatory/dermatological/respiratory conditions, e.g., ARDS). Big surge: +80.61% to \~$6.52 (volume \~28–32M shares). Reason: Momentum from promising clinical data/results in ARDS treatment (e.g., Phase 3 paridiprubart study showing mortality improvements), plus positive FDA designations boosting confidence. Broader biotech rally in small caps contributed. Insider activity: Notable recent CEO insider buying (multiple purchases reported in early March 2026, including fresh share buys signaling confidence from leadership).
* ANTX — AN2 Therapeutics, Inc. (biopharma focused on boron chemistry for infectious diseases, lead candidate epetraborole for NTM lung disease, etc.). Surge: +66.67% to \~$2.85 (volume notable). Reason: Plans to advance oral epetraborole into Phase 2 for Polycythemia Vera (PV), plus $40M private placement financing and other pipeline progress (e.g., FDA clearances for trials in M. abscessus). Biotech pipeline momentum drove gains.
* DAWN — Day One Biopharmaceuticals, Inc. (biopharma, oncology focus; OJEMDA for pediatric low-grade glioma, etc.). Huge surge: +65.88% to \~$21.20 (volume \~76M shares). Reason: Major catalyst was announcement of acquisition by Servier (French pharma) for \~$2.5B to expand rare oncology portfolio—classic M&A premium drove the spike. Also strong OJEMDA sales momentum and 2026 revenue guidance ($225M–$250M).
* TECX — Tectonic Therapeutic, Inc. (biotech developing novel therapies, e.g., TX45 for pulmonary hypertension, TX2100 for HHT).Surge: +28.80% to \~$35.87 (hit new highs around $28–$35 range). Reason: Positive Phase 1b topline data for TX45 (hemodynamic improvements in PH-HFrEF), advancing to Phase 2 trials (APEX data expected 2026), plus strong cash position/runway. Biotech clinical momentum and analyst "Buy" ratings (targets up to $81+) fueled it. Insider activity: Recent insider buying (e.g., CEO and CFO purchases in Feb 2026 at \~$21/share levels, totaling significant value; net buys over sales in recent periods).